Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin
and how well it works when given with frontline chemotherapy in treating patients with newly
diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab
ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute
lymphoblastic leukemia.
This phase II/III trial studies how well daunorubicin and cytarabine with or without
uproleselan works in treating older adult patients with acute myeloid leukemia receiving
intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may
prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with
uproleselan may work better in treating patients with acute myeloid leukemia compared to
daunorubicin and cytarabine alone.
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual
treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia
who have not received previous treatment. The addition of venetoclax to the usual treatment
might prevent chronic lymphocytic leukemia from returning. This trial also will investigate
whether patients who receive ibrutinib plus obinutuzumab plus venetoclax and have no
detectable chronic lymphocytic leukemia after 1 year of treatment, can stop taking ibrutinib.
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may
interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy,
such as venetoclax work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
ibrutinib and obinutuzumab with venetoclax may work better at treating chronic lymphocytic
leukemia compared to ibrutinib and obinutuzumab.
This clinical trial studies how well simplified patient care strategy works in decreasing
early death in patients with acute promyelocytic leukemia. Implementing simplified acute
promyelocytic leukemia guidelines along with support from acute promyelocytic leukemia
experts may decrease deaths and improve survival.
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax
work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving ibrutinib, obinutuzumab, and venetoclax may work better than giving
ibrutinib and obinutuzumab in treating patients with chronic lymphocytic leukemia.
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or
nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of
minimal residual disease, defined as the levels of a gene product called bcr-abl in the
blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer
cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and
dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic
myeloid leukemia.
This randomized phase II trial studies how well ruxolitinib phosphate and dasatinib or
nilotinib work in treating patients with chronic myeloid leukemia. Ruxolitinib, dasatinib,
and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute
lymphoblastic leukemia that has come back (relapsed) or does not response to treatment
(refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop
the growth of cancer cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management